Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01165359 · ClinicalTrials.gov registry record · Phase 1
Evaluating the Safety of ITX 5061 in Treatment-Naive Hepatitis C (HCV)-Infected Adults
A Phase 1 study of Hepatitis C, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
- 10
- Study locations
NCT01165359: Completed Phase 1 study of Hepatitis C, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
NCT01165359 is a Phase 1 study of Hepatitis C that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 30 participants, below the 1,890-participant average among 106 other Hepatitis C trials with a reported enrollment target (98% lower). The trial reports 10 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01165359, a Phase 1 study of Hepatitis C, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
- 10
- Study locations
Study Summary
Hepatitis C (HCV) is a disease that affects the liver. ITX 5061 is a new medication that is being tested to treat HCV. This study will evaluate the safety of ITX 5061 and examine different doses of the medication to evaluate which dose is the most effective at lowering the amount of HCV in the blood.
Conditions Studied
Interventions
- DRUG ITX 5061
- DRUG Placebo ITX 5061
Study Locations (10)
California
- UCLA CARE Center CRS - Los Angeles
- Ucsd, Avrc Crs - San Diego
- Ucsf Aids Crs - San Francisco
Alabama
- Alabama Therapeutics CRS - Birmingham
Maryland
- Johns Hopkins Adult AIDS CRS - Baltimore
New York
- Univ. of Rochester ACTG CRS - Rochester
North Carolina
- Duke Univ. Med. Ctr. Adult CRS - Durham
Ohio
- Univ. of Cincinnati CRS - Cincinnati
Pennsylvania
- Hosp. of the Univ. of Pennsylvania CRS - Philadelphia
Other
- Puerto Rico-AIDS CRS - San Juan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2010-09 |
| Est. Completion | 2012-03 |
| Phase | Phase 1 |
What the finished NCT01165359 record still lists
NCT01165359 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 1,890-participant average among 106 other Hepatitis C trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Hepatitis C appearing as the primary indexed condition, and to 2 interventions - of which ITX 5061 is the first listed.
NCT01165359 lists 10 locations in 8 states (California, Alabama, Maryland).
Frequently Asked Questions
What is clinical trial NCT01165359 about?
NCT01165359 is a clinical study titled "Evaluating the Safety of ITX 5061 in Treatment-Naive Hepatitis C (HCV)-Infected Adults". Hepatitis C (HCV) is a disease that affects the liver. ITX 5061 is a new medication that is being tested to treat HCV. This study will evaluate the safety of ITX 5061 and examine different doses of the medication to evaluate which dose is the most effective at lowering the amount of HCV in the blood...
What is the current status of trial NCT01165359?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2010-09. Estimated completion is 2012-03.
What conditions does trial NCT01165359 study?
This clinical trial studies the following conditions: Hepatitis C.
What interventions are being tested in trial NCT01165359?
The interventions under investigation include: ITX 5061 (DRUG), Placebo ITX 5061 (DRUG).
Who is sponsoring clinical trial NCT01165359?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01165359 being conducted?
This trial has 10 study locations across Alabama, California, Maryland, New York, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hepatitis C
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01165359's enrollment target sits among peer trials
30 83rd of 106 higher than 21 of 106 other Hepatitis C trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hepatitis C trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Drug Interaction Study Between Eltrombopag and Lopinavir/Ritonavir in Healthy Adult Subjects.
COMPLETED · Phase 1
-
Interaction of Alcohol and Highly Active Antiretroviral Therapy (HAART) in HIV/AIDS and HIV/AIDS With Hepatitis C Virus (HCV) Co-Infection
COMPLETED · Phase 1
-
Study of Bavituximab in Patients With Chronic Hepatitis C Virus Infection
COMPLETED · Phase 1
-
Open-Label Hepatic Impairment Study
COMPLETED · Phase 1
-
Cross-Over Study to Assess the Cardiovascular Effects of GSK2336805
COMPLETED · Phase 1
-
Single and Multiple Dose Evaluation of ABT-072 and to Evaluate the Effect of Food on the Pharmacokinetics of ABT-072
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia